NCT00610623

Azithromycin as a Quorum-Sensing Inhibitor for the Prevention of Pseudomonas Aeruginosa Ventilator-Associated Pneumonia

Proof of Concept Study to Investigate the Impact of Azithromycin Administered iv Versus Placebo on the Prevention of Pneumonia in Ventilated Patients Colonized by Pseudomonas Aeruginosa

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 92 (actual)
• Sponsor: Anbics Management-Services Ag · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the clinical efficacy of azithromycin, used as a quorum-sensing blocker, when compared to placebo for preventing or delaying the occurrence of pneumonia in ventilated patients colonized with Pseudomonas aeruginosa.

Conditions

• Pneumonia, Ventilator-Associated
• Pseudomonas Infections

Interventions

Type	Name	Description
DRUG	azithromycin	300 mg/day, IV from day 1 to 20
DRUG	placebo	once per day, IV from day 1 to 20

Timeline

• Start date: 2003-04-01
• Primary completion: 2005-10-01
• Completion: 2005-10-01
• First posted: 2008-02-08
• Last updated: 2008-02-08

Locations

20 sites across 6 countries: Belgium, France, Poland, Serbia and Montenegro, Spain, Switzerland